Tenaya Therapeutics Inc (OQ:TNYA)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEC
Company Contact
Address: 171 Oyster Point Blvd., Suite 500
Tel: N/A
Website: https://www.tenayatherapeutics.com
IR: See website
Key People
Faraz Ali
Chief Executive Officer, Director
Leone D. Patterson
Chief Financial and Business Officer
Timothy Hoey
Chief Scientific Officer
Whittemore Tingley
Chief Medical Officer
Business Overview
Tenaya Therapeutics, Inc. is a preclinical stage biotechnology company. The Company is focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing a pipeline of disease-modifying therapies developed using its product platforms and capabilities to target defined sub-populations of patients with rare or other prevalent forms of heart disease. The Company is advancing product candidates from three diverse product platforms, such as gene therapy, cellular regeneration, and precision medicine. It is also advancing a diverse pipeline that includes both gene therapies and small molecules. The Company's capabilities include disease models, capsid engineering, promoters and regulatory elements, drug delivery and manufacturing.
Financial Overview
For the nine months ended 30 September 2022, Tenaya Therapeutics Inc revenues was not reported. Net loss increased 94% to $90.1M. Higher net loss reflects Research and development - Balancing v increase of 98% to $65M (expense), General and administrative - Balancing increase of 49% to $17.8M (expense), Stock-based Compensation in SGA increase from $1.2M to $4.5M (expense).
Employees: 140 as of Sep 30, 2022
Reporting Currency: U.S. Dollars
Enterprise value: $9.24M as of Sep 30, 2022
Annual revenue (TTM): $0.00M as of Sep 30, 2022
EBITDA (TTM): -$112.04M as of Sep 30, 2022
Net annual income (TTM): -$116.30M as of Sep 30, 2022
Free cash flow (TTM): -$130.48M as of Sep 30, 2022
Net Debt Last Fiscal Year: N/A
Shares outstanding: 63,987,996 as of Nov 16, 2022
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.